Cargando…

Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors

Uterine smooth muscle tumors range from benign leiomyomas to malignant leiomyosarcomas. Based on numerous molecular studies, leiomyomas and leiomyosarcomas mostly lack shared mutations and the majority of tumors are believed to develop through distinct mechanisms. To further characterize the molecul...

Descripción completa

Detalles Bibliográficos
Autores principales: Mäkinen, Netta, Kämpjärvi, Kati, Frizzell, Norma, Bützow, Ralf, Vahteristo, Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463371/
https://www.ncbi.nlm.nih.gov/pubmed/28592321
http://dx.doi.org/10.1186/s12943-017-0672-1
_version_ 1783242694578929664
author Mäkinen, Netta
Kämpjärvi, Kati
Frizzell, Norma
Bützow, Ralf
Vahteristo, Pia
author_facet Mäkinen, Netta
Kämpjärvi, Kati
Frizzell, Norma
Bützow, Ralf
Vahteristo, Pia
author_sort Mäkinen, Netta
collection PubMed
description Uterine smooth muscle tumors range from benign leiomyomas to malignant leiomyosarcomas. Based on numerous molecular studies, leiomyomas and leiomyosarcomas mostly lack shared mutations and the majority of tumors are believed to develop through distinct mechanisms. To further characterize the molecular variability among uterine smooth muscle tumors, and simultaneously insinuate their potential malignant progression, we examined the frequency of known genetic leiomyoma driver alterations (MED12 mutations, HMGA2 overexpression, biallelic FH inactivation) in 65 conventional leiomyomas, 94 histopathological leiomyoma variants (18 leiomyomas with bizarre nuclei, 22 cellular, 29 highly cellular, and 25 mitotically active leiomyomas), and 51 leiomyosarcomas. Of the 210 tumors analyzed, 107 had mutations in one of the three driver genes. No tumor had more than one mutation confirming that all alterations are mutually exclusive. MED12 mutations were the most common alterations in conventional and mitotically active leiomyomas and leiomyosarcomas, while leiomyomas with bizarre nuclei were most often FH deficient and cellular tumors showed frequent HMGA2 overexpression. Highly cellular leiomyomas displayed the least amount of alterations leaving the majority of tumors with no known driver aberration. Our results indicate that based on the molecular background, histopathological leiomyoma subtypes do not only differ from conventional leiomyomas, but also from each other. The presence of leiomyoma driver alterations in nearly one third of leiomyosarcomas suggests that some tumors arise through leiomyoma precursor lesion or that these mutations provide growth advantage also to highly aggressive cancers. It is clinically relevant to understand the molecular background of various smooth muscle tumor subtypes, as it may lead to improved diagnosis and personalized treatments in the future. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-017-0672-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5463371
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54633712017-06-08 Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors Mäkinen, Netta Kämpjärvi, Kati Frizzell, Norma Bützow, Ralf Vahteristo, Pia Mol Cancer Letter to the Editor Uterine smooth muscle tumors range from benign leiomyomas to malignant leiomyosarcomas. Based on numerous molecular studies, leiomyomas and leiomyosarcomas mostly lack shared mutations and the majority of tumors are believed to develop through distinct mechanisms. To further characterize the molecular variability among uterine smooth muscle tumors, and simultaneously insinuate their potential malignant progression, we examined the frequency of known genetic leiomyoma driver alterations (MED12 mutations, HMGA2 overexpression, biallelic FH inactivation) in 65 conventional leiomyomas, 94 histopathological leiomyoma variants (18 leiomyomas with bizarre nuclei, 22 cellular, 29 highly cellular, and 25 mitotically active leiomyomas), and 51 leiomyosarcomas. Of the 210 tumors analyzed, 107 had mutations in one of the three driver genes. No tumor had more than one mutation confirming that all alterations are mutually exclusive. MED12 mutations were the most common alterations in conventional and mitotically active leiomyomas and leiomyosarcomas, while leiomyomas with bizarre nuclei were most often FH deficient and cellular tumors showed frequent HMGA2 overexpression. Highly cellular leiomyomas displayed the least amount of alterations leaving the majority of tumors with no known driver aberration. Our results indicate that based on the molecular background, histopathological leiomyoma subtypes do not only differ from conventional leiomyomas, but also from each other. The presence of leiomyoma driver alterations in nearly one third of leiomyosarcomas suggests that some tumors arise through leiomyoma precursor lesion or that these mutations provide growth advantage also to highly aggressive cancers. It is clinically relevant to understand the molecular background of various smooth muscle tumor subtypes, as it may lead to improved diagnosis and personalized treatments in the future. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-017-0672-1) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-07 /pmc/articles/PMC5463371/ /pubmed/28592321 http://dx.doi.org/10.1186/s12943-017-0672-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Mäkinen, Netta
Kämpjärvi, Kati
Frizzell, Norma
Bützow, Ralf
Vahteristo, Pia
Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors
title Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors
title_full Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors
title_fullStr Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors
title_full_unstemmed Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors
title_short Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors
title_sort characterization of med12, hmga2, and fh alterations reveals molecular variability in uterine smooth muscle tumors
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463371/
https://www.ncbi.nlm.nih.gov/pubmed/28592321
http://dx.doi.org/10.1186/s12943-017-0672-1
work_keys_str_mv AT makinennetta characterizationofmed12hmga2andfhalterationsrevealsmolecularvariabilityinuterinesmoothmuscletumors
AT kampjarvikati characterizationofmed12hmga2andfhalterationsrevealsmolecularvariabilityinuterinesmoothmuscletumors
AT frizzellnorma characterizationofmed12hmga2andfhalterationsrevealsmolecularvariabilityinuterinesmoothmuscletumors
AT butzowralf characterizationofmed12hmga2andfhalterationsrevealsmolecularvariabilityinuterinesmoothmuscletumors
AT vahteristopia characterizationofmed12hmga2andfhalterationsrevealsmolecularvariabilityinuterinesmoothmuscletumors